Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
After failure of HT, in addition to secondary hormonal manipulation (antiandrogens, ketoconazole with steroids and estrogens), these are currently the drugs approved by the US FDA for initial therapy ...
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...
Study of JAK inhibition in stem-like prostate cancer (JASPER): A phase 1/2 multicenter study of ruxolitinib and enzalutamide in castration resistant prostate cancer undergoing lineage plasticity. This ...
Despite these advances, the median survival in the first-line setting of mCRPC is approximately 20 months, and in the postdocetaxel setting is about 15 months. The modest benefits conferred to these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results